"GI ASCO Updates: Challenging Chemotherapy with Biomarker Breakthrough" and “ASCO Updates – Rad Oncology”
Objectives (a couple more to come)
Objectives:
- Define actionable alterations in second Line biliary tract cancer
- Summarize the role of KRAS in HER2 targeting strategies
- Discuss the results of improved overall survival demonstrated on the PREOPANC study with the use of neoadjuvant chemotherapy versus chemoradiation therapy.
- Discuss the use of 177Lu-PSMA-617 in the treatment of metastatic castrate resistant prostate cancer
***This session will VIRTUAL via zoom***
Zoom information:
Join from a PC, Mac, iPad, iPhone or Android device:
Please click this URL to join. https://uwmadison.zoom.us/s/97907845208?pwd=c0lldVdDa1pEUUpmdEZ1SXlpL05Ydz09
Passcode: UWCCC
Or One tap mobile:
+13126266799,,97907845208# US (Chicago)
+19292056099,,97907845208# US (New York)
Or join by phone:
Dial(for higher quality, dial a number based on your current location):
US: +1 312 626 6799 or +1 929 205 6099 or +1 301 715 8592 or +1 346 248 7799 or +1 669 900 6833 or +1 253 215 8782
Webinar ID: 979 0784 5208
International numbers available: https://uwmadison.zoom.us/u/abwFikBNtn
- 1.00 ACPE Contact Hours - Pharmacist
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC Contact Hours
- 1.00 University of Wisconsin–Madison Continuing Education Hours
- 1.00 Approved for AMA PRA Category 1 Credit™